Latest / Science Behind the Glass: illuminating the human side / Breaking Barriers: Revolutionising Science Without Animals with Dr Natalie Anderson
Transcript
- 0:01Who are the characters behind science? This is
- 0:04Science Behind the Glass, illuminating the human
- 0:06side. In this podcast, we unveil the human side
- 0:11of laboratories and science. Scientists share
- 0:14personal experiences and we discuss their meanings
- 0:17from different perspectives and fields of research.
- 0:23Welcome to Science Behind the Glass, illuminating
- 0:25the human side. The podcast where we explore
- 0:28the groundbreaking innovations that make science
- 0:31more compassionate and ethical. I'm your host.
- 0:34dr linda duran and today we are venturing into
- 0:38the transformative world of scientific research
- 0:40without animal testing a pioneer had marked by
- 0:44challenges breakthroughs and ethical milestones
- 0:48reshaping the future of research that's right
- 0:51our guest is a dedicated advocate and expert
- 0:55in this movement dr natalie anderson who has
- 0:58a phd in public health from cortin university
- 1:02a master's in Child Health Research and a Bachelor
- 1:06of Science in Human Biology. Dr. Anderson has
- 1:09made significant contributions to pediatric respiratory
- 1:13medicine, combining in silico and experimental
- 1:16methods to advance healthcare solutions. Dr.
- 1:20Anderson plays a vital role as a postdoctoral
- 1:23researcher and science outreach consultant for
- 1:26animal -free science advocacy. It's a nonprofit
- 1:29organization or NGO dedicated to replacing the
- 1:33use of animals in research, science, and teaching
- 1:36with innovative and ethical alternatives. Through
- 1:39her work, she guides researchers in adopting
- 1:42these methods and advocates for policy changes
- 1:45to foster a more compassionate and scientifically
- 1:48relevant approach. Dr. Anderson is a member of
- 1:52the Editorial Board of Alternatives to Laboratory
- 1:55Animals, a peer -reviewed journal that drives
- 1:57the development of humane and scientifically
- 1:59sound methodologies. Her efforts not only push
- 2:02the boundaries of ethical research, but also
- 2:05pave the way for a future where scientific innovation
- 2:07aligns seamlessly with moral responsibility.
- 2:11Natalie, thank you very much for accepting the
- 2:14invitation. Thanks so much, Linda. It's a real
- 2:18pleasure to be here. Thank you so much for the
- 2:20introduction. To start, your academic background
- 2:24spans multiple areas of science and health research.
- 2:28What inspired you to focus on promoting non -animal
- 2:32research methods and what led you to work in
- 2:36this? Yeah, so it was a bit of a journey, I suppose.
- 2:40Firstly, As you just introduced, I did my master
- 2:44in child health research. And for that work,
- 2:48I was doing radio labelled lung deposition studies
- 2:51in teenagers to look at if different asthma medications
- 2:55reaches the small peripheral airways where they
- 2:57have the most benefit for children with asthma.
- 3:00And we weren't allowed to do those types of studies
- 3:05because they involve radiation in small cohorts
- 3:08of children, although it was less than sort of
- 3:10it. five aeroplane flights worth of radiation
- 3:13or one x -ray but it's still an ethical consideration
- 3:17so i was already thinking at that early stage
- 3:20how i could better and more ethically investigate
- 3:23the issue of aerosol lung deposition and then
- 3:27there were some other limitations of the method
- 3:29such as we were we were imaging it was using
- 3:32two -dimensional imaging instead of three -dimensional
- 3:35because three -dimensional takes longer to image
- 3:39So there was a number of reasons, but I was already
- 3:41sort of thinking, how can we do this more ethically,
- 3:43even though those studies were in humans? Because
- 3:47of those limitations, I looked at the end of
- 3:50my masters, what other options are there? And
- 3:53computational modelling was becoming really popular
- 3:55and the computing power was increasing. And you
- 3:59need, because you need supercomputers to just
- 4:01sort of investigate using computational fluid
- 4:05dynamics, the aerosol lung deposition. And that's
- 4:09when I knew that I wanted to do a PhD using those
- 4:12computational models. And so they're also considered
- 4:16non -animal models. So that's an alternative
- 4:20to studying those in animals as well. So, yeah,
- 4:24I went on to do that for my PhD. In that space
- 4:30and while I was doing my PhD, I learnt... that
- 4:34we had a collaborator over in the US who was
- 4:37also doing these amazing computational models.
- 4:39They published a paper that was using, combining
- 4:44the in silicoid computational aerosol lung deposition
- 4:47study with some in vitro cell -based studies.
- 4:51So looking at the toxicity of a particular agrochemical
- 4:55or pesticide and those types of studies. are
- 5:00usually done in animals so they're called they're
- 5:04normally called the 90 -day inhalation toxicity
- 5:07test and it's commonly performed in rats but
- 5:11this collaborator had created these alternative
- 5:13models that were able to replace essentially
- 5:17the animal model that 90 -day study in rats and
- 5:21so I'd already seen at that point that it was
- 5:24possible and that study and that method got accepted
- 5:28by the Environmental Protection Agency in the
- 5:30US as an alternative they actually wavered the
- 5:33need for that 90 -day study so yeah that was
- 5:37sort of my first insight into that during my
- 5:39PhD through our collaborators work and so I knew
- 5:43that It was important and these models were being
- 5:47sort of accepted elsewhere in the world. And
- 5:50then I suppose the other main reason and why
- 5:52I like to promote the non -animal research methods
- 5:55is just I do have a love for animals. That's
- 5:59partly my personal experience that got me involved
- 6:01in this area. I'd ask to volunteer actually at
- 6:05Animal Free Science Advocacy or we would... We
- 6:08were then known as Humane Research Australia,
- 6:10but there was a job going. So I applied for the
- 6:13job there and I've sort of, and I got the job
- 6:15and I've not looked back ever since because really
- 6:18the non -animal models and methods of, they excite
- 6:22me as a researcher. We're always looking to sort
- 6:24of push the boundaries and this certainly ticks
- 6:28all of those non -animal models, certainly tick
- 6:30all of those boxes. Yeah, we need to sort of
- 6:34start thinking that and really considering, seriously
- 6:38that animals are sentient, they have autonomy.
- 6:42We sort of need to stop thinking of them as human
- 6:45property or tools to use in research. I think
- 6:50that's really important to advocate for that.
- 6:52Yeah, that sounds pretty interesting and very
- 6:56complex methods that you start implementing to
- 7:01overcome these necessities. And to put everything
- 7:05in context, You already explained a little bit
- 7:09why it's important, but can you expand on the
- 7:12importance in medical science to transit away
- 7:15from animal testing and in general in scientific
- 7:18research to other methodologies like these models?
- 7:24Why is this transition important? Yeah, so it
- 7:28is essential, I think, in the most obvious reason
- 7:31in Australia and throughout. throughout the world
- 7:36as well there's similar codes but we have the
- 7:39Australian code for the care and use of animals
- 7:42for scientific purposes and in that code it does
- 7:46state that animals should only be used when there's
- 7:49no scientifically valid alternative or replacement
- 7:52option for that particular test and that replacement
- 7:57for animals must be considered so there is that
- 8:00ethical and scientific obligation that's written
- 8:04in that code to do that. So that's the first
- 8:06most important reason. And I think we just have
- 8:12to remember as researchers that using animals
- 8:15in research allows you to do things to animals
- 8:17that would ordinarily be illegal. um you would
- 8:22receive a fine for those if you don't have that
- 8:24special scientific license so we we're really
- 8:27given an enormous amount of responsibility um
- 8:30as researchers and a huge amount of trust um
- 8:33to do the right thing um sometimes i think we
- 8:36we forget that we have that that huge amount
- 8:38of trust and responsibility i suppose the fact
- 8:41that searching for alternatives isn't mandated
- 8:44um although it's then to be considered in this
- 8:48code. The code is not a legislation. The code
- 8:52can be put into legislation throughout the different
- 8:56states in Australia, but it isn't a legislation
- 8:58itself. It's just an overarching guideline. So,
- 9:02yeah, it's really important that we take the
- 9:05responsibility as researchers to look for those
- 9:08alternatives and help build that trust in scientific
- 9:11research. And I suppose the second... really
- 9:15important reason why we need to transition away
- 9:17is is to stop the waste of time and money that's
- 9:21involved with animal testing the animal testing
- 9:24can take years and cost a considerable amount
- 9:26more than than the non -animal models which are
- 9:29also quicker but there's there is a huge incentive
- 9:32financially to to transition and then globally
- 9:37there there are a huge amount of drivers for
- 9:40this transition, although they're not so relevant
- 9:43to us here in Australia. But the biggest, one
- 9:46of the biggest reasons why they're pushing the
- 9:49transition to non -animal models internationally
- 9:52is to meet the demand to test industrial chemicals.
- 9:56And it might sound shocking, but it is true that
- 9:59less than 10 % of chemicals on the market today
- 10:01have been fully tested for safety. I learned
- 10:05that from the director for the OECD Environment
- 10:07Directorate. in one of their presentations. So
- 10:10it is a globally recognised issue. And the production
- 10:14of chemicals is over 1 ,000 new chemicals on
- 10:17the market every year, put on the market every
- 10:20year in the US alone. And the industrial chemical
- 10:23market is bigger than the pharmaceutical market.
- 10:27So there's a huge financial incentive to be able
- 10:31to test those to make sure that they're safe
- 10:33and to get them on the market. That's a huge
- 10:37driver. But then the pharmaceutical market is
- 10:40also massive. We've probably, maybe everyone
- 10:43has heard the stats that between 90 to 99 % of
- 10:48drugs that are tested in preclinical animal trials
- 10:52go on to fail, either due to safety or efficacy
- 10:55when they get into human clinical trials. There's
- 10:59a really low success rate of drugs getting to
- 11:02market. And that's obviously a concern for pharmaceutical
- 11:05industry. So that's another huge reason why we
- 11:08want to be pushing towards using the non -animal
- 11:11models and methods to help get treatments to
- 11:14patients faster. I think those are probably some
- 11:16of the major reasons. But I guess testing in
- 11:20animals is also quite an old science. It was
- 11:23first mandated or the need to test in animals
- 11:26was first mandated by the United States. and
- 11:28Drug Administration in 1937. So it is an old
- 11:33science and we've come a long way since then.
- 11:36And I think the technologies and methods that
- 11:40we have in the non -animal space are really very
- 11:43advanced, very advanced engineering. And so,
- 11:47yeah, we've got the tools and the methods to
- 11:50be able to transition. It's just now the cultural
- 11:52shift make to move more in that direction. Yeah,
- 11:57that's true. And something that you mentioned
- 11:59before is like, yeah, unfortunately, these guidelines
- 12:02for the use of animals in research are like a
- 12:06guideline and a suggestion, but there's not a
- 12:09law that actually enforces them. And it's pretty
- 12:12old. It's 2013, if I'm not wrong, here in Australia.
- 12:16And besides, there's no transparency. So the
- 12:22researchers are not showing. the results or how
- 12:27many animals are being used for being tested.
- 12:31And also what is really translated from the use
- 12:35of these animals, for example, in drug discovery
- 12:38or for pharmaceutical purposes or what is immunology
- 12:43or for the vaccination of making vaccines. So
- 12:48that's something that is really weak, I would
- 12:52say really weak. A lot of researchers are reluctant
- 12:56to try another test just because it has been
- 13:00done like that before. But we forget that science
- 13:04is not a religion. And in science, the idea is
- 13:08just progressing, testing, and it's like it is
- 13:11not working when we move forward. And that's
- 13:14something that needs to be mentioned. Now that
- 13:18we mentioned this part, the pharmaceutical and
- 13:21immunology have historically relied heavily on
- 13:25animal models, especially mice. What are some
- 13:28viable alternatives for these fields? How can
- 13:31researchers make transition without compromising
- 13:34safety or efficacy? Having said that, there's
- 13:39a lot of literature that shows that actually
- 13:41the animal testing doesn't translate in good
- 13:43results. For humans, as you mentioned before,
- 13:47some of them, the tests that they did in the
- 13:54lab actually doesn't work for humans. So it doesn't
- 13:58translate in anything. So end up in just a waste
- 14:01of money and resources. And unfortunately, the
- 14:05death of these animals. Yeah, that's it. They're
- 14:09all really important points to make, Gwenda.
- 14:12So as far as the viable alternatives and the
- 14:17limitations of the animal models, though, I guess
- 14:21we can't forget that using animals is just a,
- 14:25is supposed to have always been protective of
- 14:28human health. It's not supposed to be predictive
- 14:32of human health. That was never sort of the original
- 14:35idea for why animals were being used. as I mentioned,
- 14:40the first mandate to test in animals that came
- 14:43about because there were several big pharmaceutical
- 14:47scandals back in the early 1900s. And so one
- 14:55of those was the thalidomide scandal, which obviously
- 14:58resulted in a lot of birth defects in children,
- 15:01where that drug was actually promoted as a morning
- 15:06sickness drug. And then there was the sulfonamide
- 15:09scandal as well. So where the substance that
- 15:12we now know as antifreeze was being actually
- 15:15put into children's medication to make it into
- 15:18a liquid form, which was supposed to be easier
- 15:21for them to take. And that resulted in child
- 15:25death. So the requirement to test in animals
- 15:29was brought in because of those two incidents.
- 15:32um to help with the regulation of the field and
- 15:36that was to be protective of human health so
- 15:38not predictive um so i think yeah that's a really
- 15:40important distinction to make um that the animal
- 15:44models are just sort of to give a supposed to
- 15:48be to give a rough idea of what might happen
- 15:51um in a in a human and in mammal so and then
- 15:55having said that there are lots of viable alternatives
- 15:59i guess the animal models aren't necessarily
- 16:03sophisticated enough. So like I mentioned before,
- 16:0790 to 99 % of drugs tested in animals go on to
- 16:11fail in human trials. So already we know that
- 16:15the animal models are not necessarily sophisticated
- 16:17enough to determine safety and efficacy in humans,
- 16:21or that success rate may be a lot higher. So
- 16:24yeah, and I think the other important thing to
- 16:27note in the pharmaceutical area is that it's...
- 16:30the only major industrialised sector to not use
- 16:33modelling and simulation to test the safety,
- 16:35the quality and the effectiveness of products
- 16:38that are used in humans. So the cars and aircraft
- 16:42all have modelling and simulation to test the
- 16:45safety. So you think like car crash test dummies
- 16:49and that sort of thing. And that is increasingly
- 16:53being transitioned to computational modelling.
- 16:55So I think in the pharmaceutical industry, definitely
- 16:59needs to use a lot more of that just purely to
- 17:03be or should do the same thing as what the other
- 17:09industrialised sectors are doing. But there are
- 17:13already some signs that this is happening in
- 17:19the pharmaceutical industry. So, for example,
- 17:21there's what's called physiologically based pharmacokinetic
- 17:25modelling. So this kind of modelling is... computational
- 17:29it looks at the absorption the distribution metabolism
- 17:32and excretion of a drug from the body and so
- 17:36these models are definitely already being used
- 17:38to support drug applications that are made and
- 17:42there is also the virtual physiological human
- 17:47initiative was founded in 2005 and they're they're
- 17:52working towards modeling a virtual human or a
- 17:55digital human twin And these type of technologies
- 17:59can also be used in drug development. So there
- 18:04are those types that are already being used.
- 18:08And the virtual human heart is already being
- 18:12used to test some medical products, medical devices.
- 18:16So there is already evidence that it's being
- 18:19used. They're not a complete replacement for
- 18:22testing these products and drugs on animals,
- 18:24but they are already being used to complement
- 18:27that. at the moment. And they don't compromise
- 18:32the safety or efficacy, obviously, because they
- 18:34are already a bit accepted method by the regulatory
- 18:37agencies. So I think how we can transition is
- 18:41another sort of maybe separate question, because
- 18:44I think we will always be making sure that these
- 18:48alternatives don't compromise on the safety or
- 18:50efficacy. because essentially the non -animal
- 18:54models are being held to a higher standard even
- 18:57than the animal models themselves and require
- 19:01validation. And we will only be using these methods
- 19:05if they are scientifically valid. And there's
- 19:09sort of really stringent process that they have
- 19:12to take to make sure that they are validated.
- 19:18The whole idea of transitioning, I guess, is
- 19:20another thing. So, for example, there is, and
- 19:23we have to take the lead of international colleagues,
- 19:27I think, here because they are quite far advanced
- 19:30than perhaps Australia. So, for example, there's
- 19:34a test called the Monocyte Activation Test and
- 19:38it was invented in 1989. It is a test to test
- 19:42for hydrogen -causing or fever -causing substances.
- 19:46that might be in injected drugs. And that test
- 19:51was invented only eight years after we understood
- 19:54as humans how fever worked, that science started
- 19:58to understand that. And that test can be used
- 20:03to replace the rabbit pyrogen test, which was
- 20:07first invented and used in 1912. So there is
- 20:11a really long history of these tests being developed.
- 20:16the monocyte activation test was invented in
- 20:191989 but it wasn't until 2010 that it was actually
- 20:23accepted as a test and it started to replace
- 20:25the rabbit test and in 2017 there were 80 less
- 20:30rabbits being used for that test so i think it's
- 20:33a very slow process to transition but that is
- 20:36one of the particular tests that that sort of
- 20:39leads the way there that sounds very interesting
- 20:43and you you were telling us or explaining us
- 20:46a little bit that these technologies or these
- 20:48models are reliable that they are comparable
- 20:52or maybe they can be even better in terms of
- 20:57accuracy and reliability but to understand a
- 21:01little bit better how these technologies works
- 21:03can you explain what is what in silico methods
- 21:07are and how these technologies that are able
- 21:11to model tissues or organs or even organisms
- 21:15work um yes i suppose there's like you said there's
- 21:21there's the in silico methods and then there's
- 21:24in vitro methods so um and then there's sort
- 21:28of a broad um range of different approaches that
- 21:32we can take because i think partly what's required
- 21:35to make that transition to non -animal models
- 21:38is it sort of a shift away from the mentality
- 21:41that we need to test in a whole organism so that
- 21:44that is what most researchers or animal researchers
- 21:48believe is important and indeed that that has
- 21:52been in the past it certainly has been the case
- 21:54and the requirement for safety is to test in
- 21:57in the whole organism and usually in you know
- 22:01in a rat and in so in two species so it's usually
- 22:04a rat and a dog um it could be a rat and a primate
- 22:06the the alternatives are not a direct replacement
- 22:11for testing in a whole organism and i think that's
- 22:13something yeah we have to be really clear that
- 22:17it's not a a direct replacement um the alternatives
- 22:23uh take a um different approach where we're sort
- 22:29of breaking up the whole organism into little
- 22:32chunks, I suppose, and thinking of it differently.
- 22:36So the different approaches that we can think
- 22:40of to support that, I think like integrated approaches
- 22:47to testing and assessment is one sort of terminology
- 22:50that will commonly come across, which just means
- 22:53use of in silico and in vitro technologies combined.
- 22:58Like I mentioned earlier with the aerosol deposition,
- 23:02lung deposition in silico model to see where
- 23:05the drug goes in the lungs. And then once you
- 23:08know how much is going to get to the lungs, you
- 23:10can use the cell culture model to test if there'll
- 23:16be toxicity at that cellular level as well and
- 23:19combine the two. So that's what's called an integrated
- 23:22approach to testing and assessment. The integrated
- 23:26approach to testing assessment can be sort of
- 23:28combined with the adverse outcome pathway approach.
- 23:32And so the adverse outcome pathways, the concept
- 23:37for that was sort of first established around
- 23:402010, 2012. And I think first officially the
- 23:45Wikipedia, the adverse outcome pathways, there's
- 23:47a big Wikipedia and that was launched in 2014.
- 23:51And this is a huge, the adverse outcome pathways.
- 23:54approach is to help regulatory decision making
- 23:57and what an adverse outcome pathway includes
- 24:01is or the components of it is you have a molecular
- 24:05initiating event and then you have a series of
- 24:09key events at the cellular and tissue and organ
- 24:12level and they lead to some form of adversity
- 24:17or an adverse outcome in humans or at the organism
- 24:22level. or maybe the environmental level with
- 24:26animals in wildlife, for example. So, yeah, I
- 24:33think that approach of breaking it up into steps
- 24:36and each of those steps or each of those key
- 24:39events can be tested for if that is happening.
- 24:43And so you would use in vitro or in silico method
- 24:46to sort of look at those different checkpoints,
- 24:50I suppose. So, yeah, that's... Again, that's
- 24:53a bit of a shift away from what we're commonly
- 24:56used to with the animal models where you're looking
- 24:59for an apical endpoint, you're looking for something
- 25:02sort of external or some sort of organ system
- 25:07failure or cancer or some really end stage point
- 25:11that proves that there's toxicity, whereas the
- 25:14adverse outcome pathways can be traced back to
- 25:17the molecular initiating event and all of those
- 25:19key events which then lead to. you know the adverse
- 25:22outcome which could be um which it was something
- 25:26i'm trying to think of like um neurodevelopmental
- 25:29toxicity or inhalation toxicity or decreased
- 25:33lung function those kinds of things so yeah i
- 25:36think we just got to change the mentality and
- 25:39and then the specific you might be interested
- 25:42more in the what the specific sort of in silico
- 25:46and in vitro methods are um and the most common
- 25:50ones that that you will hear about is organ on
- 25:54a chip or that's also known as micro physiological
- 25:57systems and there's a sort of really a miniature
- 26:01organ on a micro scale and essentially that's
- 26:06taking a cross -section through a major functional
- 26:08biological unit so with the lung on the chip
- 26:13you've got the chip involves both airflow and
- 26:16blood flow. And it can stretch as well to mimic
- 26:20the movement of the lung and can be seeded with
- 26:25the immune cells and things. So it really does
- 26:29get can get quite complex and mimic different
- 26:31and be able to mimic different diseases as well
- 26:34that you would see. And then there's organoids
- 26:37where they're supposed to mimic an organ, obviously.
- 26:41And it has the sort of the cellular and the organ
- 26:44level. structure and they can be combined they
- 26:48can be vascularized but they can include blood
- 26:51flow as well and they can be also combined with
- 26:56organ chips but you can sort of mix the two I
- 27:00suppose and then so yeah organ on a chip organoids
- 27:04are probably the the two most common in vitro
- 27:08models although there's other 3D cell culture
- 27:10models that are that are quite advanced using
- 27:12scaffolding too. And then the in silico ones
- 27:16that are most widely known is quantitative structure
- 27:22activity relationship, which is where you identify
- 27:27the main chemical structures that would potentially
- 27:31cause some kind of sensitivity or toxicity, massive
- 27:38databases of these that can be screened. And
- 27:42then the other major, I mean, there's a whole
- 27:46sort of suite of different really. I have a question.
- 27:51For example, with like a development of vaccines,
- 27:55what are the alternatives to use the animal models?
- 28:01That's not my area of speciality, Linda, but
- 28:04I have heard recently that the... the virtual
- 28:09physiological human initiative has been working
- 28:11on a computational model for tuberculosis for
- 28:18vaccines for tuberculosis so I can't remember
- 28:21exactly what that initiative is called but yeah
- 28:25I think for there are different methods that
- 28:29can be used for vaccine batch testing though
- 28:31for example there's a huge and there's been a
- 28:34couple of a big worldwide initiative is one called
- 28:38VAC2VAC which was looking at alternatives to
- 28:43batch testing for vaccines and one of those methods
- 28:49that is included with that is the monocyte activation
- 28:52test for the pyrogens but there's another suite
- 28:57of alternative tests as well and there So the
- 29:02International Council on Animal Protection in
- 29:05pharmaceutical programs and in OECD programs
- 29:09does keep a list of all the internationally harmonised
- 29:12test guidelines that include non -animal models.
- 29:18So that's something that we can look at as well.
- 29:23And then there was a project that was led by
- 29:26the NC3Rs and the National Centre for the 3Rs
- 29:30in the UK. and that was looking at testing of
- 29:36or looking into non -animal models for testing
- 29:39of biologicals and that was in collaboration
- 29:44or requested by the World Health Organization
- 29:47so yeah I think there are some major projects
- 29:51in the areas of vaccines and biologicals but
- 29:55the actual methods that would be used would would
- 30:00still be a combination of all of them um the
- 30:03the cues are the um for the uh initial screening
- 30:08maybe although I suppose sorry that's probably
- 30:10for drugs more than um vaccines but organ on
- 30:13chip organoid there'd definitely be technologies
- 30:16that could be um utilized to to test uh vaccines
- 30:20fantastic well the biggest challenges that scientists
- 30:26are facing when they are trying to adopt these
- 30:28methodologies and how can policymakers or the
- 30:33public help overcome these obstacles? Yeah, so
- 30:37just testing policies that restrict the use of
- 30:42animals in general or for cosmetics and other
- 30:44areas, Linda. Yeah, so I think with the policies
- 30:49for cosmetics, In 2019, there was the Industrial
- 30:56Chemicals Act in Australia, and that was introduced
- 31:00along with the associated game, the Australian
- 31:03Industrial Chemicals Introduction Scheme. And
- 31:06this wasn't a complete ban on animal testing
- 31:10for cosmetics purposes. And you can look on the
- 31:13RSPCA Australia website for more information
- 31:15on that. what the Act and the Scheme introduced
- 31:18was a restriction on animal testing and that
- 31:21was introduced from the 1st of July in 2020.
- 31:25And so the restriction was on the use of new
- 31:29animal test data for introductions of chemicals
- 31:31that had an end use in cosmetics and that did
- 31:35include chemicals that are used solely for cosmetics
- 31:39but also those that have multiple end uses. one
- 31:44of which is for cosmetics. And so, yeah, animal
- 31:49welfare organisations in Australia are calling
- 31:51for the Industrial Chemicals Act to be strengthened
- 31:54and to have a legislative prohibition on testing
- 31:58for chemicals that have an end use in cosmetics.
- 32:00And so just to put that in perspective, over
- 32:0337 countries worldwide have now prohibited fully
- 32:07or in part testing for cosmetics purposes. And
- 32:14so, yeah, there's a lot more information on the
- 32:17Cruelty Free International website on the cosmetics.
- 32:20But I think what we can do with policies, you
- 32:25mentioned earlier about the Australian Code being
- 32:29a guideline rather than a legislation. And so
- 32:35it's up to the interpretation in legislation
- 32:38in the state how well enforced that is. And the
- 32:43fact that it's over 10 years old now, I think
- 32:47it would be really important to strengthen the
- 32:50language in the Australian Code and potentially
- 32:55to mandate the requirement of replacement, whether
- 33:00that's just similar to what the UK have done
- 33:04mandating that there should be funds. provided
- 33:08for for replacement development and validation
- 33:12of replacement options that could certainly be
- 33:15the case or whether we introduce what's called
- 33:20non -technical summaries so this is where once
- 33:24the research project has finished they the researchers
- 33:28are required to write up a report in that can
- 33:32be accessed by the public so it's really clearly
- 33:35written easy to understand the number of animals
- 33:39that are used, the purpose and specifically what
- 33:44replacement options the research has considered.
- 33:46So non -technical summaries are mandatory in
- 33:50Europe and so that's something as well that we
- 33:55could be looking to do in Australia and we at
- 33:58the moment the consultations have just closed
- 34:02actually but there was a consultation on an options
- 34:06paper for national statistics reporting of animal
- 34:11use in Australia because as you mentioned we
- 34:14don't there's no requirement to publicly report
- 34:18on the number of animals that are used in research
- 34:22and teaching and science in Australia it's up
- 34:26to the states whether or not they do publicly
- 34:28report that and several states do certainly not
- 34:31all so yeah that would be another really important
- 34:34thing is that we actually have that accountability
- 34:38to the public of the number of animals that are
- 34:41used so that they're aware of the issue. I think
- 34:44most people will be surprised that six million
- 34:46animals are used every year for biomedical research.
- 34:50And even more people might be surprised that
- 34:53there's almost 300 primates being used in research
- 34:56in Australia at the moment. So I think it's really
- 34:59important that people are aware of what's happening
- 35:03and that would help them to be able to make more
- 35:05informed decisions on this. So, yeah, I think
- 35:10that those are really important things that we
- 35:13need to do in Australia. That's right. And, well,
- 35:18you've been explaining so far that we have seen...
- 35:23many significant advancements in the development
- 35:28of these alternative technologies, right? But
- 35:33do you consider that there are areas of research
- 35:37where these alternatives are still underdeveloped?
- 35:42How do you see science may address these gaps
- 35:45in the future? Yeah, so there's definitely areas
- 35:49where the non -animal models are more developed
- 35:51than others and there is still a way to go for
- 35:55sure. So I think the areas that the non -animal
- 35:59technologies are more developed is obviously
- 36:01areas where there have been more public scrutiny
- 36:04or a larger amount of animals being used or there's
- 36:08a bigger problem with the animal model not translating
- 36:11to human outcomes. So, for example, with rare
- 36:13diseases. And, yeah, so the non -animal models
- 36:18that are more developed are those that can replace
- 36:20the test for cosmetic purposes. I described earlier
- 36:25there's either a full or partial prohibition
- 36:30on that in many countries worldwide. So those
- 36:32are the models that are really quite well developed,
- 36:35particularly for eye irritation testing, for
- 36:38example. There's been a huge amount of progress
- 36:40with that. Then, yeah. For rare diseases, whether
- 36:46animal models, they can't translate either due
- 36:49to the species or genetic differences. So that's
- 36:52another area where there's a lot more advancement
- 36:55in the non -animal model development. But I think
- 37:00what everyone is waiting for, I think, is for
- 37:03a complete non -animal model organism. Because,
- 37:08like I said, that's the current argument. We
- 37:11need to test in a whole living organism. And
- 37:14to the best of my knowledge, there's no non -animal
- 37:17model that can completely replace that full living
- 37:20organism yet. Like I mentioned, it's partly because
- 37:23we actually need to shift our approach and our
- 37:26thinking to look at things more mechanistically.
- 37:30And this is really a benefit, I think. And we
- 37:34gain a lot more information from the models and
- 37:37they're a lot more complex and a lot more detailed
- 37:40understanding of human biology can be. can be
- 37:44achieved with the with the non -animal models
- 37:47than testing in in other non -human animals so
- 37:50yeah i think the gap and i guess the gap are
- 37:55not that the non -animal technologies don't exist
- 37:59it's just they need to sort of be refined um
- 38:03we need to shift our thinking um a lot of the
- 38:07hard work is already done there is a lot of legislation
- 38:10in place already like in the UK with the mandating
- 38:14funding for replacement, with the latest, the
- 38:19FDA Modernisation Act in 2023, that speaking
- 38:24about, well, that introduced the terms for non
- 38:28-clinical, including in vitro and in silico methods,
- 38:32so that legislation has now changed and you don't
- 38:35have to purely use animals anymore, although
- 38:38there's, again, more work to do to sort of ensure
- 38:41that that. breaches that's fully enforced, but
- 38:45the legislative changes, there are some legislative
- 38:49changes that are being made as well. So there
- 38:52is a lot of work that's already been done to
- 38:54sort of bridge the gap barriers to the uptake
- 38:58of non -animal models and methods. But I think
- 39:02a big gap at the moment that still exists is
- 39:05we're still utilising the idea of the three R's.
- 39:11um and that was i think uh sort of first came
- 39:14about in 19 i'm gonna say 1959 it was around
- 39:19then by russell and birch um so it's yeah it's
- 39:22over how many years old 60 years old now um that
- 39:27the idea of the three r's um which is uh replacement
- 39:31reduction and refinement of animal use I think,
- 39:35yeah, we need to be much more shifting towards
- 39:38just replacement. Although there is still a space
- 39:43for reduction and refinement, but in some areas
- 39:46of animal research, maybe veterinary and other
- 39:50areas, there is still a need for some of those.
- 39:53But I think with biomedical research, we really
- 39:55need to be shifting towards more replacement
- 39:58and for pharmaceutical testing. and regulatory
- 40:02testing on industrial chemicals that sort of
- 40:06thing we really need to sort of get away from
- 40:08that mentality and that's a bit of a gap at the
- 40:11moment is that we still we haven't kind of let
- 40:14go of that old concept But, yeah, I think it's
- 40:17really exciting. The idea of a future without
- 40:20animal testing is really exciting and I think
- 40:22we have so much of the technology already and
- 40:25it's just the case of refining that. It's the
- 40:27case of keep pushing this new paradigm. Yeah,
- 40:31I think, you know, maybe we're not so far away
- 40:34from what we see in some of the sci -fi movies
- 40:36where, you know, there's a machine that can heal
- 40:40the body. Maybe we're not so far away from that
- 40:42as we think, I think. but we need to make sure
- 40:45that we invest the funding, we invest the people
- 40:48to do the work. Yeah, I think it's really important
- 40:52to push that. It's exciting for what we can achieve,
- 40:55I think, with human innovation. Yeah, that's
- 40:59true. Hopefully it's going to be applied in all
- 41:03the countries. Yeah. And having said that, now
- 41:08that you mentioned before the Australia update,
- 41:11the animal testing policies. restricting the
- 41:14use of animals in cosmetics but how animal how
- 41:17australia sits compared to global laws and what
- 41:21needs to be done to create a ethical scientific
- 41:25landscape good question um how do we compare
- 41:31to internationally so i think well i guess in
- 41:36that regard i would start with the fact that
- 41:38unfortunately australia is one of only nine oecd
- 41:41countries to not have a centre for alternatives
- 41:43to animal testing. And this is a real limitation
- 41:47because a lot of the, it basically just means
- 41:50there's no funding going into that centre. There's
- 41:53no funding in non -animal technologies and models
- 41:57as currently in Australia, no funding streams
- 42:01specifically available. for that either by our
- 42:04national health and medical research council
- 42:06or through our medical research future fund unfortunately
- 42:09neither of them are providing funding solely
- 42:12for non -animal model development and validation
- 42:16and so that is yeah that that's disappointing
- 42:19overseas there is a lot of money going into this
- 42:22um for example the nc3rs in the uk um has uh
- 42:27they've just actually doubled their budget so
- 42:29it was 10 million pounds and so it's have recently
- 42:32been doubled to $20 million. In the US, there's
- 42:35huge amounts of money going into the various
- 42:38different funding schemes. The same in Europe.
- 42:42Animal Free Science Advocacy have a business
- 42:46case that you can see online for the funding
- 42:49that is available. Also in the CSIRO Futures
- 42:53non -animal model strategy for Australia. They've
- 42:57got a bit of an international comparison on how
- 43:00much money is being put into the non -animal
- 43:03technologies overseas compared to here. And so,
- 43:07yes, it is a little bit disappointing. And the
- 43:10World Congress on Alternatives to Animal Use
- 43:14in the Life Sciences is being held in Brazil
- 43:16next year. So that's really exciting. But Australia
- 43:20has not ever hosted a World Congress, although
- 43:23there's been 13. 13 so I think it will be 14
- 43:27next year actually so yeah it would be yeah to
- 43:31put Australia on the map I think that's something
- 43:33that we really need to do is to host a world
- 43:36congress that yeah there's a lot of a lot of
- 43:40limitations I'm not sure specifically the The
- 43:46legislation or differences between Australia
- 43:49and other countries, I could not probably speak
- 43:51to that. But, yeah, certainly the limitation
- 43:55of funding, the fact that we don't have a centre
- 43:57for alternatives and we've never hosted the World
- 44:00Congress, those are limitations. Because, as
- 44:04we know, when you're attending conferences, it's
- 44:07a huge opportunity to collaborate and to build
- 44:10networks. and to link in with what other countries
- 44:14are doing and to progress the field. So, yeah,
- 44:19it is a bit of a limitation. Having said that,
- 44:23this year was, I think, I believe the first year
- 44:26that the conference, which was first established
- 44:30in Australia, called Organoid Zara. This was
- 44:34the first year that that was actually... uh held
- 44:37in thailand um and it became a sort of an asia
- 44:40pacific conference which was really fantastic
- 44:42to see um so that that was really exciting um
- 44:47but yeah i think we we definitely need to collaborate
- 44:50and um get to some of these world summits or
- 44:54world congresses um participate in the international
- 44:57areas yeah that sounds nice And finally, what
- 45:03do you think about the use of certificates or
- 45:06animal test -free stamps that industries or products
- 45:10can obtain? Do you think that this helps to incentivize
- 45:14more conscious consumption and more responsible
- 45:16production by the industry? Yeah, I mean, I'm
- 45:19not really an expert on consumer habits. If industrial
- 45:24use of these kind of stamps would help with the
- 45:29uptake, but I can't. because a consumer myself.
- 45:32And so I think what I personally want to know
- 45:35if I'm buying products is that they're vegan.
- 45:37Do they have the international leaping bunny
- 45:40on them, which is the internationally recognised
- 45:43symbol that guarantees no new animal tests were
- 45:47used in the development of any product that's
- 45:50displaying it. So I personally do look for that
- 45:54on products. I think there are people similar
- 45:57to me as well. that would certainly not want
- 46:01to buy something without that on it. So I think
- 46:03as a consumer, I can certainly say it is important.
- 46:07And yeah, I think if there's some kind of certification
- 46:10that companies can get, we should always be striving
- 46:14to do better. And yeah, I think that is really
- 46:18important. I mean, maybe one day that can be
- 46:20the case for pharmaceuticals. We're probably
- 46:24a long way off of that, but yeah, it would be.
- 46:27that would be of interest to me as well. I don't
- 46:30know if that could happen with the pharmaceutical
- 46:32area too. So yeah, just speaking as a consumer
- 46:36there. Yeah, I agree. Like transparency. I think
- 46:40that with any product, that would be really good.
- 46:43Yeah, yeah, exactly. Yeah, yeah. As a consumer,
- 46:46it's really important to know what's happened
- 46:48with the product and have that accountability
- 46:50by the companies, yeah. Thank you very much,
- 46:54Natalie, for all this amazing information. Yeah,
- 46:57thanks very much, Linda. I really appreciate
- 46:59the opportunity. This episode was inspired by
- 47:03the courage to challenge tradition and push science
- 47:05towards a more ethical future. Dr. Natalie's
- 47:08journey reminds us that science isn't just about
- 47:10breaking truths. It's about compassion, responsibility,
- 47:13and the choices we make to improve human health
- 47:16without harm. We hope this conversation has left
- 47:19you feeling inspired, empowered, and curious
- 47:21about the future of medicine. because change
- 47:24starts with those willing to ask, is there a
- 47:26better way? Science Behind the Glass is independently
- 47:30produced and edited by your host, with the invaluable
- 47:33support of our technical director, Rafael Giordano,
- 47:37and original music by our talented friend, Bernardo
- 47:41Aguila. Stay connected with us on Instagram,
- 47:44X, Facebook, and LinkedIn, and visit our website
- 47:47for updates and stories. Don't forget to subscribe
- 47:50and share this podcast with your friends and
- 47:52colleagues to amplify these important narratives.
- 47:55If you have been moved by our mission, we invite
- 47:58you to support us via PayPal. Just click the
- 48:01Support Us button on our website. Your support
- 48:04helps keep this project alive and thriving. Thanks
- 48:07for listening. Keep observing, wondering, and
- 48:09protecting the small wonders of our world. Until
- 48:12next time.